AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
Keep up to date on AgNovos events and related news
AgNovos Healthcare will participate in the “Osteologie Kongress” in Salzburg from March 12th - 14th.
AgNovos Healthcare will participate in the WCO in Barcelona from April 2nd – 5th, 2020.
AgNovos Healthcare will participate in the “Alterstraumatologie Kongress” in Munich from March 19th - 20th where we will exhibit the CE-marked OSSURE LOEP kit.
The study titled Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures (RESTORE) is a randomized, controlled, prospective, single blinded, multi-national study.
AgNovos Healthcare will participate at DKOU in Berlin from October 22nd to 25th, 2019.
The German broadcast channel NDR published a television report about new treatment methods for local osteoporotic bone loss.